AUG 13, 2026 · PHASE 1/2 TRIAL
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
ClinicalTrials.gov
Phase 1/2 trial in early stage of recruitment with no results yet posted; primary outcomes are safety and dose-finding rather than efficacy.
Reported
Planned enrollment315
Study phasePhase 1/2
Primary outcome: Incidence of dos…first 21 days of dose escalation phase